Research

Hormonal

Tirzepatid (GIP/GLP-1 agonist) provides superior weight loss and glycemic control compared to Semaglutid in patients with Type 2 Diabetes and Obesity.

If oral medications and lifestyle changes are insufficient, Tirzepatid (10-15mg weekly) is currently the most effective pharmacological option for weight loss and blood sugar control in Type 2 Diabetes, outperforming Semaglutid. Discuss this with your doctor to see if it's appropriate for your specific health profile.

StrongSupportsVERY_HIGH confidence
Letztlich konnte für 10 mg bzw. 15 mg Tirzepatid eine klare Überlegenheit im Vergleich zu Semaglutid sowohl hinsichtlich HbA1c (p = 0,002) als auch Gewichtsreduktion (p < 0,001) gezeigt werden [46].
Johanna M. Brix et al. · Wiener klinische Wochenschrift · 2026

Why this rating

Based on SURPASS 2, a high-quality phase 3 RCT.

Source

Adipositas und Diabetes mellitus Typ 2 (Update 2026)

Johanna M. Brix et al. · Wiener klinische Wochenschrift · 2026

DOI 10.1007/s00508-026-02706-y

narrative_review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →